Brief: Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial In CDI Patients
29/01/2024 14:04
Jan 29 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* ACURX ANNOUNCES POSITIVE EXTENDED CLINICAL CURE DATA FOR
IBEZAPOLSTAT FROM PHASE 2B CLINICAL TRIAL IN CDI PATIENTS
* ACURX PHARMACEUTICALS- IN PHASE 2B TRIAL, 100% OF
IBEZAPOLSTAT-TREATED PATIENTS WHO AGREED TO OBSERVATION FOR UP
TO 3 MONTHS FOLLOWING CLINICAL CURE OF CDI EXPERIENCED NO
RECURRENCE OF INFECTION
* ACURX PHARMACEUTICALS- FURTHER ANALYSES WILL BE
FORTHCOMING AS
DATA BECOME AVAILABLE REGARDING EFFECTS ON BILE ACID METABOLISM
& PHARMACOKINETIC DATA
* ACURX PHARMACEUTICALS INC - IBEZAPOLSTAT CONTINUES TO
DEMONSTRATE SUCCESS COMPARED TO A STANDARD OF CARE, ORAL
VANCOMYCIN, TO TREAT PATIENTS WITH CDI
* ACURX PHARMACEUTICALS INC - ANTICIPATE CONTINUED FAVORABLE
DIFFERENTIATION BETWEEN TWO THERAPEUTIC OPTIONS IN 2024
Source text for Eikon: ID:nPn9wJL9Na
Further company coverage: ACXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acurx Pharmaceuticals
See all newsAcurx Pharmaceuticals Q1 net loss narrows as expenses fall
Brief: Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business Update
Brief: Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend
Acurx Pharma Q3 net loss narrows to $2 mln